Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease lung disease
Phenotype |cystic fibrosis
Sentences 64
PubMedID- 23226468 The university of north carolina committee for the rights of human subjects approved the collection and use of excess surgical pathology tissue, obtained at the time of lung transplant, from patients with advanced lung disease associated with cystic fibrosis.
PubMedID- 25725986 Background: although recent studies have begun to elucidate how airway microbial community structure relates to lung disease in cystic fibrosis (cf), microbial community activity and the host's response to changes in this activity are poorly understood.
PubMedID- 24062613 High-producer tgfβ1 genotypes are associated with severe lung disease in cystic fibrosis (cf), but studies combining il-8, tnfα-, and tgfβ1(+genotype) levels and their impact on cf lung disease are scarce.
PubMedID- 22608703 Background: it is not known whether antibiotic therapy for lung disease in cystic fibrosis (cf) has an influence on circulating polymorphonuclear neutrophil (pmn) function and apoptosis.
PubMedID- 26079395 Does the fef25-75 or the fef75 have any value in assessing lung disease in children with cystic fibrosis or asthma.
PubMedID- 20840889 Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it.
PubMedID- 25973994 The spectrum of nocardia lung disease in cystic fibrosis.
PubMedID- 24429095 We discuss treatment strategies including new drugs that are being developed and their potential role in the treatment of early lung disease in patients with cystic fibrosis.
PubMedID- 25339567 In this paper, we present three different cases of mycobacterial lung disease in patients with cystic fibrosis.
PubMedID- 21220215 Reports from the seventies and eighties have shown that cystic fibrosis (cf) patients with severe lung disease have high levels of igg and that this is associated with worse prognosis.
PubMedID- 22323305 Rationale: unrecognized airway infection and inflammation in young children with cystic fibrosis (cf) may lead to irreversible lung disease; therefore early detection and treatment is highly desirable.
PubMedID- 23633344 Background: nebuliser systems are used to deliver medications to control the symptoms and the progression of lung disease in people with cystic fibrosis.
PubMedID- 22538801 Rationale: airways obstruction and lung volume restriction, major features of lung disease in cystic fibrosis (cf), may regress independently, causing dysanapsis between these parameters.
PubMedID- 22429393 Post transplant survival data are similar to those reported for other lung diseases treated with transplantation, including cystic fibrosis and emphysema.
PubMedID- 23076917 Authors' conclusions: there is currently no evidence to support the use of cftr gene transfer reagents as a treatment for lung disease in people with cystic fibrosis.
PubMedID- 22664493 Study of heterozygotes may elucidate the pathogenesis of lung disease in cystic fibrosis.
PubMedID- 20435528 Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: three areas for future research which areas to target.
PubMedID- 19895389 Lung transplantation is the only life-prolonging therapy available for cystic fibrosis (cf) patients with end-stage lung disease.
PubMedID- 22960983 What you don't know can hurt you; early asymptomatic lung disease in cystic fibrosis.
PubMedID- 26047144 lung disease in cystic fibrosis involves decreased mucociliary clearance, repetitive pulmonary infections, inflammation and ultimately bronchiectasis leading to reduced lung function, loss of quality of life and premature death [2].
PubMedID- 21494150 Purpose of review: lung disease in cystic fibrosis (cf) results from chronic airway infection and inflammation leading to progressive bronchiectasis and respiratory failure.
PubMedID- 19931415 Fat-free mass depletion in cystic fibrosis: associated with lung disease severity but poorly detected by body mass index.
PubMedID- 26429870 The purpose of this study was to evaluate cardiorespiratory fitness and reasons for exercise curtailment in a contemporary adult cystic fibrosis (cf) cohort with mild lung disease.
PubMedID- 20427819 The development of lung disease in cystic fibrosis pigs.
PubMedID- 26453627 Further issues that require attention are organ transplantation and end of life management.lung disease in adults with cystic fibrosis drives most of the clinical care requirements, and major life-threatening complications, such as respiratory infection, respiratory failure, pneumothorax and haemoptysis, and the management of lung transplantation require expertise from trained respiratory physicians.
PubMedID- 21462361 Genetic studies of lung disease in cystic fibrosis (cf) are hampered by the lack of a severity measure that accounts for chronic disease progression and mortality attrition.
PubMedID- 20955240 It is the main cause of hospital-acquired pneumonia and of lung disease in patients with cystic fibrosis, as well as infections in patients with neutropenia and burns (pier and ramphal, 2005).
PubMedID- 25124441 lung disease in people with cystic fibrosis (cf) is initiated by defective host defense that predisposes airways to bacterial infection.
PubMedID- 23235684 Authors' conclusions: this review did not find any evidence for the effectiveness of different antimicrobial treatment for nontuberculous mycobacteria lung disease in people with cystic fibrosis.
PubMedID- 23378408 Hrct has an advantage over conventional chest x-rays in the evaluation of the stage and progression of lung disease in patients with cystic fibrosis.
PubMedID- 24884656 Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease.
PubMedID- 21955231 lung disease in cystic fibrosis (cf) is typified by the development of chronic airways infection culminating in bronchiectasis and progression to end-stage respiratory disease.
PubMedID- 21382942 cystic fibrosis and survival in patients with advanced lung disease.
PubMedID- 20717938 Summary: lung disease in patients with cystic fibrosis (cf) is characterized by recurrent bacterial respiratory infections and intense airway inflammation.
PubMedID- 22436723 The natural history of progression of lung disease in cystic fibrosis (cf) usually consists of a sequential acquisition of infecting organisms [2], the most significant acquisition being infection with pseudomonas aeruginosa.
PubMedID- 24282073 Authors' conclusions: there is currently no evidence to support the use of cftr gene transfer agents as a treatment for lung disease in people with cystic fibrosis.
PubMedID- 25929952 Percentages of airway cxcr4(+) granulocytes correlated with lung disease severity in patients with cystic fibrosis.these studies demonstrate that chronic fungal colonisation with a.
PubMedID- 25478180 Background: lung clearance index (lci) derived from sulfur hexafluoride (sf6) multiple breath washout (mbw) is a sensitive measure of lung disease in people with cystic fibrosis (cf).
PubMedID- 25861303 cystic fibrosis is associated with chronic lung disease, poor digestion, malabsorption of nutrients, and malnutrition [3].
PubMedID- 23743112 Pseudomonas aeruginosa in patients without cystic fibrosis is strongly associated with chronic obstructive lung disease.
PubMedID- 22241570 Background: gastro-esophageal reflux (gor) may contribute to lung disease in children with cystic fibrosis (cf).
PubMedID- 25624972 lung disease in cystic fibrosis results from chronic airway infection and inflammation leading to progressive bronchiectasis and respiratory failure [38].
PubMedID- 23460012 As a result of their underlying lung disease, patients with cystic fibrosis (cf) have a higher risk of developing nontuberculous mycobacteria (ntm) infections compared with the general population.
PubMedID- 25410840 The progression of lung disease in cystic fibrosis (cf) reduces the ability ofindividuals to participate in physical activity.
PubMedID- 26022611 Background: to assess the severity of lung disease in cystic fibrosis (cf), scoring systems based on chest radiographs (cxrs), ct and mri have been used extensively, although primarily in research settings rather than for clinical purposes.
PubMedID- 25102015 Antioxidant supplementation for lung disease in cystic fibrosis.
PubMedID- 22162514 Regional differences in the evolution of lung disease in children with cystic fibrosis.
PubMedID- 26383963 Association of chronic candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis.
PubMedID- 22898134 Chronic lung disease in cystic fibrosis (cf) is characterized by bacterial infection and intense, neutrophil-dominated airway inflammation.
PubMedID- 25470304 Authors' conclusions: this review did not find any evidence for the effectiveness of different antimicrobial treatment for nontuberculous mycobacteria lung disease in people with cystic fibrosis.

Page: 1 2